Search results for "dosing"

showing 10 items of 128 documents

Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varice…

2016

Background Varicella is a highly infectious disease with a significant public health and economic burden, which can be prevented with childhood routine varicella vaccination. Vaccination strategies differ by country. Some factors are known to play an important role (number of doses, coverage, dosing interval, efficacy and catch-up programmes), however, their relative impact on the reduction of varicella in the population remains unclear. This paper aims to help policy makers prioritise the critical factors to achieve the most successful vaccination programme with the available budget. Methods Scenarios assessed the impact of different vaccination strategies on reduction of varicella disease…

Budgets0301 basic medicineMalePediatricsNational Health ProgramsNational Health ProgramDiseaseVaricella0302 clinical medicineChickenpoxEpidemiology030212 general & internal medicineChildChickenpox Vaccineeducation.field_of_studyChickenpoxlcsh:Public aspects of medicineImmunization ProgramVaccinationvirus diseasesCoverage; Dosing interval; Efficacy; Routine varicella vaccination impact; VaricellaVaccinationItalyBudgetDosing intervalFemalePublic HealthResearch ArticleHumanmedicine.medical_specialtyCoverageAdolescentEfficacy030106 microbiologyPopulationSocio-culturaleVaccines AttenuatedMass VaccinationRoutine varicella vaccination impactChickenpox Vaccine03 medical and health sciencesCoverage; Dosing interval; Efficacy; Routine varicella vaccination impact; Varicella; Public Health Environmental and Occupational HealthmedicineHumansDosingeducationImmunization Programsbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthlcsh:RA1-1270Models Theoreticalmedicine.diseaseVaccine efficacybusinessBMC Public Health
researchProduct

Impact of Undernutrition on the Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: A Literature Review

2017

The etiology of undernourishment in cancer patients is multifactorial: tumor-related mechanisms (such as obstruction, metabolic abnormalities, and functionality changes) in addition to the influence of anticancer therapies, which can induce or worsen undernutrition. The evident role of undernutrition in cancer treatment outcomes suggests the need of considering nutritional status when evaluating anticancer drugs. In order to merge the available data and offer researchers and clinicians a global view of this phenomenon, the present manuscript reviews on a drug-by-drug basis the undernutrition-related pharmacokinetic and pharmacodynamic aspects of anticancer treatments. This review notes inte…

Cancer ResearchMedicine (miscellaneous)Antineoplastic AgentsPharmacologyBioinformatics030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineOtotoxicityPharmacokineticsmedicineHumansAnthracyclinesDosingVinca AlkaloidsEtoposideCardiotoxicityNutrition and Dieteticsbusiness.industryMalnutritionNeurotoxicitymedicine.diseaseCancer treatmentMalnutritionMethotrexateOncology030220 oncology & carcinogenesisFluorouracilPharmacodynamic aspectsbusinessNutrition and Cancer
researchProduct

Diagnosis of pregnancy-associated venous thromboembolism - position paper of the Working Group in Women’s Health of the Society of Thrombosis and Hae…

2016

Venous thromboembolism (VTE) is a major cause of maternal morbidity during pregnancy and the postpartum period. However, because there is a lack of adequate study data, management strategies for pregnancy-associated VTE must be deduced from observational stu-dies and extrapolated from recommendations for non-pregnant patients. In this review, the members of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH) have summarised the evidence that is currently available in the literature to provide a practical approach for treating pregnancy-associated VTE. Because heparins do not cross the placenta, weight-adjusted therapeutic-dose low molecular weight heparin …

Diagnostic Imagingmedicine.medical_specialtyConsensusmedicine.drug_classPregnancy Complications CardiovascularLow molecular weight heparinFibrin Fibrinogen Degradation ProductsPredictive Value of TestsPregnancyRisk FactorsHumansMedicinecardiovascular diseasesDosingIntensive care medicineVenous ThrombosisPregnancybusiness.industryWarfarinReproducibility of ResultsVenous Thromboembolismmedicine.diseasePulmonary embolismVenous thrombosisFemaleObservational studyPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessBiomarkersPostpartum periodmedicine.drugVasa
researchProduct

Aloin delivery on buccal mucosa: ex vivo studies and design of a new locoregional dosing system

2014

Context: Chemoprevention of potential malignant disorders or cancerous lesions that affect oral mucosae requires extended duration of treatment. Locoregional delivery of natural products could represent a promising strategy for this purpose. Objective: To investigate the aptitude of aloin to permeate through, or accumulate in, the buccal mucosa and to develop a new prolonged oro-mucosal drug delivery system. Materials and Methods: Permeation/accumulation of aloin from Curacao Aloe (containing 50% barbaloin) was evaluated ex vivo, using porcine buccal mucosa as the most useful model to simulate human epithelium. Oro-mucosal matrix tablets were prepared by dispersing aloin (10% w/w) in Eudrag…

DrugEmodinPolymersSwinemedia_common.quotation_subjectChemistry PharmaceuticalAcrylic ResinsPharmaceutical ScienceDentistryAloinPharmacologyFriabilityPermeabilityBarbaloin buccal tablets aloin matrix tablets oro-mucosal delivery locoregional drug delivery buccal mucosa.chemistry.chemical_compoundDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoverymedicineAnimalsDosingAloemedia_commonPharmacologybusiness.industryOrganic ChemistryMouth MucosaAdhesivenessReproducibility of ResultsPermeationDrug LiberationchemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverySwellingmedicine.symptombusinessEx vivoTablets
researchProduct

Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Phar…

2011

The renin-angiotensin-aldosterone system (RAAS) plays a dominant role in the pathophysiology of hypertension, diabetes mellitus, chronic kidney disease and chronic heart failure. Therefore, drugs that block key components of the RAAS such as ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs) have gained wide clinical use for these indications. Despite progress, the morbidity and mortality of patients treated with ACEI or ARBs remain high. Aliskiren (Tekturna, Rasilez) is the first orally active inhibitor of renin approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg. Aliskiren is effective …

DrugRamiprilbusiness.industrymedia_common.quotation_subjectlcsh:RPharmaceutical ScienceCorrectionlcsh:Medicinelcsh:RS1-441AliskirenPharmacologylcsh:Pharmacy and materia medicachemistry.chemical_compoundIrbesartanAliskiren 300 MGn/achemistryDrug DiscoverymedicineMolecular MedicineDosing intervalbusinessmedia_commonmedicine.drugPharmaceuticals
researchProduct

Weight-based dosing: Which impact on efficacy and safety of therapy?

2004

Abstract Pegylated interferons (PEG-IFNs) in combination with ribavirin represent the most recent advance in the treatment of patients withchronic hepatitis C (CHC): two large clinical trials have shown a superior efficacy in clearing HCV in almost 60% of treated naive patients. Responses to antiviral treatment of CHC vary according to both viral and host factors. Managing patients with CHC infection requires individualised treatment strategies to optimise outcomes. Several landmark publications on PEG-IFNs have reported that weight is a significant predictive factor for SVR in the treatment of CHC with fixed-dose drug administration. With fixed-dose treatment, there is a direct correlation…

Drugmedicine.medical_specialtymedia_common.quotation_subjectChronic hepatitis Cchemistry.chemical_compoundPegylated interferonInternal medicinemedicineDosingAdverse effectmedia_commonHepatologybusiness.industryWeight-based dosingRibavirinGastroenterologyvirus diseasesHepatitis Cmedicine.diseaseSurgeryClinical trialchemistrybusinessWeight based dosingPegylated interferonmedicine.drugDigestive and Liver Disease
researchProduct

Prophylaxis In Congenital Factor VII Deficiency, Indications, Efficacy and Safety: Results of the STER

2010

Abstract Abstract 665 Introduction Prophylaxis is considered a difficult endeavour in FVII deficiency, especially because of the very short FVII zymogen and FVIIa half-lives, mainly in childhood. The Seven Treatment Evaluation Registry (STER, www.targetseven.org) is a prospective observational, multi-centre, web-based registry concerned with the evaluation of treatments for spontaneous bleeding episodes, surgery and prophylaxis in patients with FVII deficiency. As regards prophylaxis, STER provides the frame for a structured and detailed data capture aiming at: a) identifying patients in whom prophylaxis is advisable, b) defining clinical settings in which prophylaxis is necessary and c) de…

Gastrointestinal bleedingPediatricsmedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyHemarthrosismedicine.diseaseBiochemistryRegimenConcomitantSeverity of illnessmedicineProphylaxis in Factor VII deficiency inherited Factor VII deficiencyObservational studyDosingFresh frozen plasmabusinessBlood
researchProduct

Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients

2013

The introduction of tacrolimus in clinical practice has improved patient survival after organ transplant. However, despite the long use of tacrolimus in clinical practice, the best way to use this agent is still a matter of intense debate. The start of the genomic era has generated new research areas, such as pharmacogenetics, which studies the variability of drug response in relation to the genetic factors involved in the processes responsible for the pharmacokinetics and/or the action mechanism of a drug in the body. This variability seems to be correlated with the presence of genetic polymorphisms. Genotyping is an attractive option especially for the initiation of the dosing of tacrolim…

Graft Rejectionmedicine.medical_specialtyCYP3A5ATP Binding Cassette Transporter Subfamily BCYP3A4Genotypemedicine.medical_treatmentPharmacologyLiver transplantationBioinformaticsOrgan transplantationTacrolimusCalcineurin inhibitorMedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsDosingATP Binding Cassette Transporter Subfamily B Member 1Topic HighlightKidney transplantLiver transplantKidney transplantationBiotransformationPolymorphism Geneticbusiness.industryPharmacogeneticGraft SurvivalGastroenterologyABCB1General Medicinemedicine.diseaseKidney TransplantationTacrolimusLiver TransplantationSingle nucleotide polymorphismTransplantationsurgical procedures operativePhenotypeTreatment OutcomePharmacogeneticsTacrolimuSettore BIO/14 - FarmacologiaPersonalized medicinebusinessPharmacogeneticsImmunosuppressive Agents
researchProduct

Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie.

2017

Hintergrund und Ziele Die Behandlung schwerer dermatologischer Autoimmunerkrankungen und der toxischen epidermalen Nekrolyse (TEN) mit hochdosierten intravenosen Immunglobulinen (IVIg) ist ein bewahrtes therapeutisches Verfahren in der Dermatologie. Da eine IVIg‐Therapie in der Regel nur bei seltenen Erkrankungen oder bei schweren Fallen in Betracht gezogen wird, stutzt sich die Anwendung von Immunglobulinen zumeist nicht auf Daten aus randomisierten kontrollierten Studien, wie sie in der evidenzbasierten Medizin erforderlich sind. Da Indikationen fur die Anwendung von IVIg selten sind, ist es unwahrscheinlich, dass solche Studien in absehbarer Zeit durchgefuhrt werden. Wegen der hohen Kost…

Gynecologymedicine.medical_specialtytherapyexpert consensusbusiness.industryDermatologyautoimmune diseases dosing therapy expert consensus decision treedosing030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisdecision treemedicineautoimmune diseasesbusinessJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized c…

2018

Aims To compare the time spent in specified glycaemic ranges in people with type 1 diabetes (T1D) during 5 consecutive days of moderate-intensity exercise while on either 100% or 75% of their usual insulin degludec (IDeg) dose. Materials and methods Nine participants with T1D (four women, mean age 32.1 ± 9.0 years, body mass index 25.5 ± 3.8 kg/m2 , glycated haemoglobin 55 ± 7 mmol/mol (7.2% ± 0.6%) on IDeg were enrolled in the trial. Three days before the first exercise period, participants were randomized to either 100% or 75% of their usual IDeg dose. Participants exercised on a cycle ergometer for 55 minutes at a moderate intensity for 5 consecutive days. After a 4-week wash-out period,…

Insulin degludecType 1 diabetesbusiness.industryEndocrinology Diabetes and MetabolismArea under the curve030209 endocrinology & metabolism030204 cardiovascular system & hematologymedicine.diseaseCrossover study03 medical and health sciences0302 clinical medicineEndocrinologyRegular exerciseAnesthesiaInternal MedicineMedicineAnalysis of varianceDosingbusinessBody mass index
researchProduct